NASDAQ$DH
Definitive Healthcare Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Definitive Healthcare's first quarter revenue increased, but the company experienced a net loss, though adjusted EBITDA margin was strong due to focus on operational efficiencies.
Definitive Healthcare reported a 7% year-over-year increase in revenue to $63.5 million for Q1 2024. The company's net loss was $(12.7) million, but adjusted EBITDA was $20.0 million, representing 32% of revenue. The company grew its enterprise customer base by 6% year-over-year, ending the quarter with 559 enterprise customers.
- Revenue was $63.5 million, a 7% increase from $59.2 million in Q1 2023.
- Net Loss was $(12.7) million, or (20%) of revenue, compared to $(16.0) million, or (27%) of revenue in Q1 2023.
- Adjusted Net Income was $13.0 million, compared to $9.1 million in Q1 2023.
- Adjusted EBITDA was $20.0 million, or 32% of revenue, compared to $15.7 million, or 26% of revenue in Q1 2023.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$63.5M
Forward guidance
Definitive Healthcare provided financial guidance for Q2 2024 and full year 2024.
Tailwinds
- Revenue is expected to be in the range of $62.0 – $63.5 million for Q2 2024, a 2-4% increase year over year.
- Adjusted Operating Income is expected to be in the range of $17.0 – $18.5 million for Q2 2024.
- Adjusted EBITDA is expected to be in the range of $18.5 – $20.0 million for Q2 2024, with a 30-32% adjusted EBITDA margin.
- Adjusted Net Income is expected to be $13.5 – $14.5 million for Q2 2024.
- Revenue is expected to be in the range of $255 – $261 million for full year 2024, a 1-4% increase from the prior year.
Headwinds
- Adjusted Net Income Per Diluted Share is expected to be $0.08 – $0.09 per share on approximately 157.2 million weighted-average shares outstanding for Q2 2024.
- Adjusted Operating Income is expected to be in the range of $75.0 – $78.0 million for full year 2024.
- Adjusted EBITDA is expected to be in the range of $81.5 – $84.5 million for full year 2024, for a full-year adjusted EBITDA margin of 32-33%.
- Adjusted Net Income is expected to be $56.5 – $59.5 million for full year 2024.
- Adjusted Net Income Per Diluted Share is expected to be $0.36 – $0.38 per share on approximately 157.5 million weighted-average shares outstanding for full year 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro